Palo Santo Fund

Palo Santo is a venture capital firm specializing in psychedelic healthcare and therapies, with a mission to revolutionize mental health treatment. Founded in 2020, Palo Santo operates with a clear focus on advancing the development of psychedelic-based treatments for conditions like depression, PTSD, and addiction. With an initial fund of $35 million, the firm supports a wide range of companies working on groundbreaking solutions in biopharma, digital therapeutics, and healthcare services. Their portfolio includes over 20 companies such as atai Life Sciences, Field Trip Health, Bexson Biomedical, and Reset Pharma. The firm’s leadership is guided by top-tier experts in the psychedelic space, including Co-Founder Tim Schlidt, who is passionate about expanding access to mental health treatments. They are supported by a renowned advisory board made up of thought leaders like Dr. Charles Nichols, a professor and pioneering researcher in psychedelics, and Dr. Julie Holland, a psychiatrist and author focused on drug policy reform and clinical research into psychedelic therapies. This interdisciplinary approach enables Palo Santo to navigate the complex regulatory and scientific challenges in this emerging industry. Palo Santo's strategy emphasizes not just the scientific advancement of psychedelics, but also their affordability and accessibility for patients. They aim to scale clinically effective treatments by investing in companies that are making significant strides in the mental health sector. Their goal is to bring psychedelic therapies into the mainstream, addressing the growing global mental health crisis with innovative, science-backed solutions.